C-peptide vs Epoetin Alfa
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and Epoetin Alfa (Recombinant human erythropoietin alfa) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | C-peptide | Epoetin Alfa |
|---|---|---|
| Category | Pain Management | Muscle & Performance |
| Full Name | Connecting peptide (C-peptide) | Recombinant human erythropoietin alfa |
| Molecular Weight | 3020.3 Da | ≈30,400 Da |
| Half-Life | ~20-30 min | ~4-13 h IV; ~20-30 h SC |
| Amino Acids | 31 | 165 |
| Typical Dose | no approved analgesic dose|research-only | 50-100 IU/kg SC 3x weekly or 40,000 IU SC weekly |
| Route | IV|subQ | Subcutaneous/IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 320 |
| Research Status | Pre-clinical | Clinical |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
Epoetin Alfa Benefits
- ✓raises hemoglobin
- ✓increases oxygen-carrying capacity
- ✓may increase VO2 max
- ✓improves time-to-exhaustion
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
Epoetin Alfa Dosing
50-100 IU/kg subcutaneous 3x weekly|40,000 IU subcutaneous weekly|Titrate to hemoglobin target under medical supervision
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
Epoetin Alfa Side Effects
- ⚠hypertension
- ⚠thrombosis
- ⚠polycythemia
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
Epoetin Alfa
Human studies in anemia and performance-related settings show that increasing red-cell mass can improve aerobic capacity and endurance. It remains heavily regulated because excessive erythropoiesis raises thrombotic and cardiovascular risk.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.